NCT00801671

Brief Summary

The purpose of this study is to determine whether CPAP is effective in the treatment of systemic hypertension.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 2008

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2008

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2008

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 3, 2008

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

June 17, 2011

Status Verified

June 1, 2011

Enrollment Period

2.7 years

First QC Date

June 19, 2008

Last Update Submit

June 15, 2011

Conditions

Keywords

obstructive sleep apneaobstructive sleep apnea syndromehypertensionsystemic hypertensionambulatory blood pressure monitoring

Outcome Measures

Primary Outcomes (1)

  • Ambulatory blood pressure monitoring over 24 hours, at inclusion visit (day=0), before cPAP (3-9 weeks) and after 3 weeks of cPAP.

    24 hours

Study Arms (2)

1

ACTIVE COMPARATOR
Procedure: cPAP

2

SHAM COMPARATOR
Procedure: cPAP

Interventions

cPAPPROCEDURE

After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)

12

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • male/female over than 18 years old
  • patient with an obstructive sleep apnea (apnea-hypopnea index \> or equal to 15)
  • patient with weak or moderate hypertension (140 \<= SBP \< 180 mmHg and 90 \<= DBP \< 110 mmHg)
  • negative pregnancy test
  • ambulatory patient
  • patient who have signed the informed consent form

You may not qualify if:

  • pregnant or nursing woman
  • woman who refuses to use contraceptive method
  • acute hepatic failure, biliary cirrhosis, cholestasis
  • clearance of Cockcroft \< 30 ml/min/1.73m2
  • kaliemia \>= 5.5 mmol/l
  • acute hypertension (SBP\>= 180 mmHg and/or DBP \>= 110 mmHg)
  • acute daytime sleepiness (Epworth rating scale \> 15)
  • patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment
  • known cardiovascular pathologies
  • contraindication to CPAP
  • allergy to valsartan and/or amlodipine
  • patient treated with lithium
  • patient on tutelle or curatelle
  • patient kept in detention, major protected by the law, hospitalized person patient currently participating in another clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Russian Cardiologe Research and Production Complex

Moscow, 121552, Russia

Location

Related Publications (1)

  • Litvin AY, Sukmarova ZN, Elfimova EM, Aksenova AV, Galitsin PV, Rogoza AN, Chazova IE. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-35. doi: 10.2147/VHRM.S40231. Epub 2013 May 10.

MeSH Terms

Conditions

Sleep Apnea, ObstructiveHypertension

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Alexandr Yu Litvin, MD

    Russian Cardiology Research and Production Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 19, 2008

First Posted

December 3, 2008

Study Start

September 1, 2008

Primary Completion

June 1, 2011

Study Completion

June 1, 2011

Last Updated

June 17, 2011

Record last verified: 2011-06

Locations